CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines for serious diseases, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's senior management team will deliver a presentation on Wednesday, February 5, 2025, at 2:00 p.m. ET.
The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section. Interested parties can view the fireside chat through the investor relations portal at https://crisprtx.gcs-web.com/events. The recording will remain available for replay on the company's website for 14 days after the presentation.
CRISPR Therapeutics (Nasdaq: CRSP), un'azienda biofarmaceutica specializzata in medicinali basati sui geni per malattie gravi, ha annunciato la sua partecipazione alla prossima Guggenheim SMID Cap Biotech Conference. Il team di gestione senior dell'azienda presenterà un intervento mercoledì 5 febbraio 2025, alle 14:00 ET.
La presentazione sarà accessibile tramite una diretta streaming sul sito web dell'azienda nella sezione 'Eventi e Presentazioni'. Le parti interessate potranno seguire il colloquio attraverso il portale delle relazioni con gli investitori all'indirizzo https://crisprtx.gcs-web.com/events. La registrazione rimarrà disponibile per la visione per 14 giorni dopo la presentazione.
CRISPR Therapeutics (Nasdaq: CRSP), una empresa biofarmacéutica especializada en medicamentos basados en genes para enfermedades graves, ha anunciado su participación en la próxima Guggenheim SMID Cap Biotech Conference. El equipo de alta dirección de la empresa realizará una presentación el miércoles 5 de febrero de 2025 a las 2:00 p.m. ET.
La presentación será accesible a través de una transmisión en vivo en el sitio web de la empresa en la sección 'Eventos y Presentaciones'. Las partes interesadas podrán ver la charla a través del portal de relaciones con inversores en https://crisprtx.gcs-web.com/events. La grabación estará disponible para su reproducción en el sitio web de la empresa durante 14 días después de la presentación.
CRISPR Therapeutics (Nasdaq: CRSP), 심각한 질병을 위한 유전자 기반 의약품을 전문으로 하는 생명공학 기업이 구겐하임 SMID Cap 생명공학 컨퍼런스에 참석한다고 발표했습니다. 회사의 고위 경영진 팀은 2025년 2월 5일 수요일 오후 2시 ET에 발표를 진행할 예정입니다.
발표는 회사 웹사이트의 '이벤트 및 발표' 섹션에서 라이브 웹캐스트를 통해 접근할 수 있습니다. 관심 있는 분들은 https://crisprtx.gcs-web.com/events에서 투자자 관계 포털을 통해 대화에 참여할 수 있습니다. 발표 후 14일 동안 회사 웹사이트에서 다시 시청할 수 있는 녹화본이 제공됩니다.
CRISPR Therapeutics (Nasdaq: CRSP), une entreprise biopharmaceutique spécialisée dans les médicaments basés sur les gènes pour les maladies graves, a annoncé sa participation à la prochaine Guggenheim SMID Cap Biotech Conference. L'équipe de direction senior de l'entreprise fera une présentation le mercredi 5 février 2025 à 14h00 ET.
La présentation sera accessible via un webinaire en direct sur le site Web de l'entreprise, dans la section 'Événements et Présentations'. Les parties intéressées peuvent suivre la discussion via le portail des relations avec les investisseurs à l'adresse https://crisprtx.gcs-web.com/events. L'enregistrement sera disponible pour une relecture sur le site de l'entreprise pendant 14 jours après la présentation.
CRISPR Therapeutics (Nasdaq: CRSP), ein biopharmazeutisches Unternehmen, das auf genbasierte Medikamente für schwere Krankheiten spezialisiert ist, hat seine Teilnahme an der bevorstehenden Guggenheim SMID Cap Biotech Conference angekündigt. Das Management-Team des Unternehmens wird am Mittwoch, den 5. Februar 2025, um 14:00 Uhr ET eine Präsentation halten.
Die Präsentation wird über einen Live-Stream auf der Unternehmenswebsite im Bereich 'Veranstaltungen und Präsentationen' zugänglich sein. Interessierte können das Gespräch über das Investor-Relations-Portal unter https://crisprtx.gcs-web.com/events verfolgen. Die Aufzeichnung wird 14 Tage nach der Präsentation auf der Unternehmenswebsite für die Nachverfolgung verfügbar sein.
- None.
- None.
ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 2:00 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How long will the CRSP Guggenheim Conference webcast be available for replay?
Where can I watch CRISPR Therapeutics' (CRSP) Guggenheim Conference presentation?
What type of presentation will CRSP deliver at the Guggenheim SMID Cap Biotech Conference?
